FMR LLC funds trim Structure Therapeutics (GPCR) ADS holdings

Rhea-AI Filing Summary

FMR LLC, a 10% owner of Structure Therapeutics Inc. (GPCR), reported several sales of American Depositary Shares on January 15, 2026 through affiliated F-Prime funds. The trades, coded as open-market sales, included transactions such as 465 ADS at $82.10, 330 ADS at $83.35, 552 ADS at $84.22 and 20 ADS at $85.04 for F-Prime Capital Partners Life Sciences Advisors Fund VI LP, and larger blocks like 5,477 ADS at $82.10, 3,880 ADS at $83.35, 6,498 ADS at $84.22 and 230 ADS at $85.04 for F-Prime Capital Partners Life Sciences Fund VI LP.

After these trades, affiliated persons and entities whose holdings are reported by FMR LLC still held 4,546,674 ADS, while the two F-Prime funds held 5,005 ADS and 58,864 ADS, respectively. Each ADS represents three ordinary shares of Structure Therapeutics. The filing notes these positions are reported indirectly and includes a disclaimer that the reporting parties are not admitting beneficial ownership of the securities.

Insider Trade Summary

Net Seller: 17,452 shares ($1,453,753)

Net Sell 11 txns

Insider FMR LLC

Role 10% Owner

Sold 17,452 shs ($1.45M)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	465	$82.10	$38K
Sale	American Depositary Shares	330	$83.35	$28K
Sale	American Depositary Shares	552	$84.22	$46K
Sale	American Depositary Shares	20	$85.04	$2K
Sale	American Depositary Shares	5,477	$82.10	$450K
Sale	American Depositary Shares	3,880	$83.35	$323K
Sale	American Depositary Shares	6,498	$84.22	$547K
Sale	American Depositary Shares	230	$85.04	$20K
holding	American Depositary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 5,005 shares (Indirect, F-Prime Capital Partners Life Sciences Advisors Fund VI LP); Ordinary Shares — 20,502 shares (Indirect, F-Prime Capital Partners Life Sciences Advisors Fund VI LP)

Footnotes (1)

1. Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $82.00 to $82.37. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $83.00 to $83.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $84.00 to $84.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $85.02 to $85.06. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FMR LLC

(Last) (First) (Middle)

245 SUMMER STREET

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remark 1

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								20,502	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Ordinary Shares								241,275	I	F-Prime Capital Partners Life Sciences Fund VI LP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(1)							(1)	(1)	Ordinary Shares	4,546,674		1,515,558	I	Shares held by persons and entities whose shares are subject to reporting by the undersigned
American Depositary Shares	(1)	01/15/2026		S			465	(1)	(1)	Ordinary Shares	1,395	$82.1(2)	5,005	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(1)	01/15/2026		S			330	(1)	(1)	Ordinary Shares	990	$83.35(3)	4,675	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(1)	01/15/2026		S			552	(1)	(1)	Ordinary Shares	1,656	$84.22(4)	4,123	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(1)	01/15/2026		S			20	(1)	(1)	Ordinary Shares	60	$85.04(5)	4,103	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(1)	01/15/2026		S			5,477	(1)	(1)	Ordinary Shares	16,431	$82.1(2)	58,864	I	F-Prime Capital Partners Life Sciences Fund VI LP LP
American Depositary Shares	(1)	01/15/2026		S			3,880	(1)	(1)	Ordinary Shares	11,640	$83.35(3)	54,984	I	F-Prime Capital Partners Life Sciences Fund VI LP
American Depositary Shares	(1)	01/15/2026		S			6,498	(1)	(1)	Ordinary Shares	19,494	$84.22(4)	48,486	I	F-Prime Capital Partners Life Sciences Fund VI LP
American Depositary Shares	(1)	01/15/2026		S			230	(1)	(1)	Ordinary Shares	690	$85.04(5)	48,256	I	F-Prime Capital Partners Life Sciences Fund VI LP

Explanation of Responses:

1. Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.

2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $82.00 to $82.37. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

3. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $83.00 to $83.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

4. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $84.00 to $84.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

5. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $85.02 to $85.06. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

	/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FMR LLC report in this Form 4 for GPCR?

FMR LLC, as a 10% owner of Structure Therapeutics Inc. (GPCR), reported multiple open-market sales of American Depositary Shares on January 15, 2026 made through affiliated F-Prime funds.

Which entities actually sold Structure Therapeutics ADS in this filing?

The sales were made indirectly through F-Prime Capital Partners Life Sciences Advisors Fund VI LP and F-Prime Capital Partners Life Sciences Fund VI LP, which are associated with FMR LLC.

What were some of the sale prices and sizes reported for GPCR ADS?

Examples include sales of 465 ADS at $82.10, 330 ADS at $83.35, 552 ADS at $84.22, 20 ADS at $85.04, and larger blocks like 5,477 ADS at $82.10, 3,880 ADS at $83.35, 6,498 ADS at $84.22 and 230 ADS at $85.04.

How many Structure Therapeutics ADS do the F-Prime funds hold after these transactions?

Following the reported trades, F-Prime Capital Partners Life Sciences Advisors Fund VI LP held 5,005 ADS, and F-Prime Capital Partners Life Sciences Fund VI LP held 58,864 ADS.

What is the total indirect ADS position reported by FMR LLC in GPCR?

The filing shows 4,546,674 American Depositary Shares held by persons and entities whose shares are subject to reporting by FMR LLC, in addition to the F-Prime fund positions.

How many ordinary shares does each Structure Therapeutics ADS represent?

Each American Depositary Share represents three ordinary shares of Structure Therapeutics Inc., as disclosed in the explanatory footnotes.

Does FMR LLC admit beneficial ownership of the GPCR shares reported?

No. A remark states that the filing shall not be deemed an admission that the reporting parties are the beneficial owners of any securities reported for Section 16 or other purposes.